
Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

Sanofi and IGM Biosciences Inc. in $6.15bn deal
Under the agreement, IGM Biosciences Inc. (Mountain View) will discover IgM antibody agonists against three oncology targets and...

Avantium closes financing for FDCA plant
Polyethylene furanoate (PEF) is 100% fossil-free when made from 2,5-furandicarboxylic acid (FDCA) with fructose as a carbon source und...

Switzerland paves the way for genome editing
Following in the footsteps of the UK, Switzerland wants to exempt genome editing and targeted mutagenesis in plant breeding from the Swiss Genetic...

Biotalys’ first proteinbased biocontrol shows up in vineyards
Biotalys, the agricultural Technology (AgTech) company in Ghent (Belgium) and listed at EURONEXT (Euronext - BTLS) is devolping protein-based...

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...